HealthEquity (HQY)
(Delayed Data from NSDQ)
$98.82 USD
+1.62 (1.67%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $98.64 -0.18 (-0.18%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$98.82 USD
+1.62 (1.67%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $98.64 -0.18 (-0.18%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth D Momentum B VGM
Zacks News
Here's Why HealthEquity (HQY) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Walgreens (WBA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Strength in U.S. Healthcare and International businesses is likely to drive Walgreens' (WBA) first-quarter 2024 performance.
3 Reasons to Hold Inspire Medical (INSP) Stock in Your Portfolio
by Zacks Equity Research
Inspire Medical's (INSP) focus on R&D raises optimism about the stock.
The Zacks Analyst Blog Highlights Medpace, Elevance Health and HealthEquity
by Zacks Equity Research
Medpace, Elevance Health and HealthEquity are part of the Zacks top Analyst Blog
3 Reasons to Hold Zimmer Biomet (ZBH) Stock in Your Portfolio
by Zacks Equity Research
Zimmer Biomet's (ZBH) focus on emerging markets raises optimism about the stock.
Does HealthEquity (HQY) Have the Potential to Rally 31.37% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 31.4% upside potential for HealthEquity (HQY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Three Reasons to Add Ecolab (ECL) Stock to Your Portfolio
by Zacks Equity Research
Ecolab's (ECL) focus on R&D raises optimism about the stock.
3 Amazing Health Service Stocks to Brave "Labordemic" in 2024
by Urmimala Biswas
Here are the three stocks, MEDP, ELV and HQY, which have the potential to shield your portfolio from the impact of healthcare staffing challenges in 2024.
3 Reasons to Retain Nevro (NVRO) in Your Portfolio for Now
by Zacks Equity Research
Investors continue to be optimistic about Nevro (NVRO) due to its R&D edge.
5 MedTech Stocks Poised to Continue Their Winning Streaks in 2024
by Zacks Equity Research
Stocks like DexCom Inc. (DXCM), Integer Holdings (ITGR), Penumbra (PEN), Haemonetics (HAE), Health Equity (HAE) and are likely to continue their strong performance in 2024.
McKesson (MCK) Announces Availability of PNH's FDA-Approved Drug
by Zacks Equity Research
The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for PNH.
Three Reasons to Add DaVita (DVA) Stock to Your Portfolio
by Zacks Equity Research
DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
by Zacks Equity Research
PacBio's (PACB) product development activities raise optimism about the stock.
Here's Why You Should Retain Veeva Systems (VEEV) Stock Now
by Zacks Equity Research
Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.
QuidelOrtho's (QDEL) Latest FDA Nod to Boost Diagnostic Testing
by Zacks Equity Research
QuidelOrtho's (QDEL) receipt of the FDA's latest approval is likely to improve clinical care, provide cost savings and deliver sample-to-result molecular testing across all laboratory settings.
Reasons to Add Integer Holdings (ITGR) to Your Portfolio Now
by Zacks Equity Research
Integer Holdings' (ITGR) research and product development activities and a solid foothold in the broader MedTech space raise optimism about the stock.
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
Veeva Systems (VEEV) Vault Quality Offerings Adopted by Recipharm
by Zacks Equity Research
Veeva Systems' (VEEV) Vault Quality Suite applications are expected to aid Recipharm in boosting its operational efficiencies.
3 Reasons to Add HealthEquity (HQY) Stock to Your Portfolio
by Zacks Equity Research
HealthEquity's (HQY) strength in HSA raises optimism about the stock.
Glaukos' (GKOS) iDose TR Gets FDA Nod for Glaucoma Treatment
by Zacks Equity Research
The FDA approval of Glaukos' (GKOS) iDose TR is likely to reshape glaucoma care. A micro-invasive breakthrough promises proactive, durable treatment, heralding a new era in eye health.
DexCom's (DXCM) G7 CGM Connects With Tandem's Insulin Pump
by Zacks Equity Research
Dexcom's (DXCM) G7 integrates with Tandem's t:slim X2, revolutionizing diabetes care. A perfect combination of accuracy and innovation, this synergy sets a new standard in continuous glucose monitoring.
Molina (MOH) to Pay Lower Price for California Medicare Buyout
by Zacks Equity Research
Molina Healthcare's (MOH) new price for Bright HealthCare's California Medicare business constitutes 23% of the anticipated $1.8 billion premium revenues for 2023.
Here's Why You Should Retain QuidelOrtho (QDEL) Stock for Now
by Zacks Equity Research
QuidelOrtho's (QDEL) strong product portfolio raises optimism about the stock.
Reasons to Add DexCom (DXCM) Stock to Your Portfolio Now
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
Glaukos (GKOS) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.